Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.86 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 0.86 |
| ▸ | NEK2 | P51955 | 3/20 | 0.86 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.86 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.86 |
| ▸ | PIM1 | P11309 | 2/20 | 0.86 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.86 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.86 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.86 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.86 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.86 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.86 |
| ▸ | STK10 | O94804 | 1/20 | 0.86 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.86 |
| ▸ | KIT | P10721 | 1/20 | 0.86 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.86 |
| ▸ | GRK4 | P32298 | 1/20 | 0.86 |
| ▸ | TIE1 | P35590 | 1/20 | 0.86 |
| ▸ | FLT3 | P36888 | 1/20 | 0.86 |
| ▸ | PRKCI | P41743 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4562944 | 1.00 | PLK1 (0.86) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Hydrochloric Acid SCHEMBL3111856 | 0.99 | PLK1 (0.85) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Hydrochloric Acid SCHEMBL3107975 | 0.99 | PLK1 (0.85) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL2973906 | 0.93 | PLK1 (0.88) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL4395540 | 0.92 | PLK1 (0.73) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL4276841 | 0.92 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL29655945 | 0.92 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL310080 | 0.92 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| Gsk-461364 SCHEMBL29360650 | 0.92 | PLK1 (1.00) | PLK1PLK3NEK2PIK3CDPDGFRB | |
| SCHEMBL14568675 | 0.92 | PLK1 (0.81) | PLK1PLK3NEK2PIK3CDPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236954-B2 | Processes for preparing benzimidazole thiophenes | GLAXOSMITHKLINE LLC (US) | 2012-08-07 | — | — | US | claimed |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | claimed |
| EP-2170871-A2 | PROCESSES FOR PREPARING BENZIMIDAZOLE THIOPHENES | GlaxoSmithKline LLC (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009002916-A2 | PROCESSES FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | claimed |
| US-8236954-B2 | Processes for preparing benzimidazole thiophenes | GLAXOSMITHKLINE LLC (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236954-B2 | Processes for preparing benzimidazole thiophenes | GLAXOSMITHKLINE LLC (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236954-B2 | Processes for preparing benzimidazole thiophenes | GLAXOSMITHKLINE LLC (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| EP-1937671-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SmithKline Beecham Corporation (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| WO-2007030366-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030361-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030361-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | ABCB1, ABCG2, CYP3A5 | PLK1 344/4885PLK3 934/4885NEK2 2296/4885 |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | TPMT, TBKBP1, TYMP | PLK1 735/4885PLK3 982/4885NEK2 774/4885 |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | PLK1 458/4885PLK3 1235/4885NEK2 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.